Department of Urology, Hospital Clínic, Barcelona, Spain.
Anticancer Res. 2010 Oct;30(10):4369-72.
The usefulness of interleukin 6 (IL-6) and its soluble receptor IL-6sR in the prediction of the biochemical recurrence was evaluated in patients with prostate cancer treated with radical prostatectomy.
IL-6 and sIL-6R serum levels were measured in 96 patients with prostate cancer.
Using the log-rank test, it was evident that patients with preoperative serum levels of IL-6 higher than 1.2 pg/ml had a significantly increased probability of biochemical recurrence (p=0.031). We also observed that the Gleason score was associated with the risk of progression (p=0.033), but no relation was observed with TNM classification, PSA, % free PSA or sIL-6R. In a multivariate analysis, only IL-6 serum levels remained as a predictor of biochemical recurrence (p=0.040).
The results presented here demonstrated the usefulness of IL-6 in predicting the biochemical progression of prostate cancer, pointing towards an association between inflammation and the aggressiveness of the tumor.
评估白细胞介素 6(IL-6)及其可溶性受体 IL-6sR 在接受根治性前列腺切除术治疗的前列腺癌患者中的预测生化复发的有用性。
对 96 例前列腺癌患者的血清 IL-6 和 sIL-6R 水平进行了测量。
通过对数秩检验,术前血清 IL-6 水平高于 1.2 pg/ml 的患者发生生化复发的概率明显增加(p=0.031)。我们还观察到,Gleason 评分与进展风险相关(p=0.033),但与 TNM 分类、PSA、%游离 PSA 或 sIL-6R 无关。在多变量分析中,只有血清 IL-6 水平仍然是生化复发的预测因素(p=0.040)。
本研究结果表明 IL-6 可用于预测前列腺癌的生化进展,提示炎症与肿瘤侵袭性之间存在关联。